A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial
Cockcroft, John R.
MetadataShow full item record
Background Ethnicity, along with a variety of genetic and environmental factors, is thought to influence the efficacy of antihypertensive therapies. Current UK guidelines use a “black versus white” approach; in doing so, they ignore the United Kingdom's largest ethnic minority: Asians from South Asia. Study design The primary purpose of the AIM-HY INFORM trial is to identify potential differences in response to antihypertensive drugs used as mono- or dual therapy on the basis of self-defined ethnicity. A multicenter, prospective, open-label, randomized study with 2 parallel, independent trial arms (mono- and dual therapy), AIM-HY INFORM plans to enroll a total of 1,320 patients from across the United Kingdom. Those receiving monotherapy (n = 660) will enter a 3-treatment (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od), 3-period crossover, lasting 24 weeks, whereas those receiving dual therapy (n = 660) will enter a 4-treatment (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od), 4-period crossover, lasting 32 weeks. Equal numbers of 3 ethnic groups (white, black/black British, and Asian/Asian British) will ultimately be recruited to each of the trial arms (ie, 220 participants per ethnic group per arm). Seated, automated, unattended, office, systolic blood pressure measured 8 weeks after each treatment period begins will serve as the primary outcome measure. Conclusion AIM-HY INFORM is a prospective, open-label, randomized trial which aims to evaluate first- and second-line antihypertensive therapies for multiethnic populations.
American Heart Journal;
Mukhtar, O., Cheriyan, J., Cockcroft, J.R., Collier, D., Coulson, J.M., Dasgupta, I., Faconti, L., Glover, M., Heagerty, A.M., Khong, T.K., Lip, G.Y., Mander, A.P., Marchong, M.N., Martin, U., McDonnell, B. et al (2018) 'A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono-or dual therapy) on the basis of ethnicity: The comparIson of Optimal Hypertension Regimens; part of the Ancestry Informative Markers in Hypertension program—AIM-HY INFORM trial', American Heart Journal, 204, pp.102-108.
Article published in American Heart Journal, available open access at https://doi.org/10.1016/j.ahj.2018.05.006
Cardiff Metropolitan University (Grant ID: Cardiff Metropolian (Internal))
Showing items related by title, author, subject and abstract.
Mughal, Durre (Cardiff Metropolitan University, 2015)This 9100 word creative portfolio with an accompanying 5781 word critical reflection explores the themes of mental health and ‘writing therapy’. Melancholia is about a girl in her early twenties who suffers from anxiety ...
Effects of combining physical activity with psychotherapy on mental health and well-being: A systematic review Thomas, Jennifer; Thirlaway, Kathryn; Bowes, Nicola; Meyers, Rob (Elsevier, 2020-01-15)Objective : Despite a vast evidence-base advocating the psychological benefits of physical activity, relatively little is understood about how combining physical activity with psychological therapies may influence these ...
Intratympanic glucocorticosteroid therapy for idiopathic sudden hearing loss: meta-analysis of randomized controlled trials Lai, Dan; Zhao, Fei; Jalal, Nasim; Zheng, Yun (Lippincott, Williams and Wilkins, 2017-12-01)Background and objective: Glucocorticoids are the standard treatment for idiopathic sudden sensorineural hearing loss (ISSNHL), but whether intratympanic or systemic therapy is superior remains controversial. Previous ...